Impact of Neoadjuvant Chemotherapy on Immunohistochemical Receptor Status and Long-Term Treatment Outcomes in Locally Advanced Breast Cancer: A Comparative Analysis
Authors
Furqat Axmedov, Kahharov А.J.
Share
Annotation
Locally advanced breast cancer (LABC) presents a formidable challenge within global oncology due to its increasing incidence rates, high mortality, and the urgent need for improved diagnostic and therapeutic approaches. This study investigated the impact of neoadjuvant chemotherapy (NAC) on the immunohistochemical (IHC) receptor status in LABC patients and its correlation with long-term treatment outcomes. A total of 115 patients with locally advanced breast cancer were subjected to NAC, with subsequent analysis of changes in IHC status. Comparative assessments of overall and disease-free survival were conducted between patients with altered and unaltered IHC status post-NAC. The study identified significant differences in survival outcomes based on IHC status changes, highlighting the potential prognostic value of such alterations. The findings underscore the critical need for a more comprehensive understanding of tumor response mechanisms to NAC and its implications for personalized therapeutic strategies. These insights have significant implications for advancing tailored treatment approaches for LABC patients.
Keywords
Authors
Furqat Axmedov, Kahharov А.J.
Share
References:
- Dhanushkodi M, Sridevi V, Shanta V, Rama R, Swaminathan R, Selvaluxmy G, Ganesan TS. Locally Advanced Breast Cancer (LABC): Real-World Outcome of Patients From Cancer Institute, Chennai. JCO Glob Oncol. 2021 May;7:767-78 doi: 10.1200/GO.21.00001
- Nielsen SR, Schmid MC. Macrophages as Key Drivers of Cancer Progression and Metastasis. Mediators Inflamm. 2017;2017:9624760. doi: 10.1155/2017/9624760
- Bishara LA, Machour FE, Awwad SW, Ayoub N. NELF complex fosters BRCA1 and RAD51 recruitment to DNA damage sites and modulates sensitivity to PARP inhibition. DNA Repair (Amst). 2021 Jan;97:103025. doi: 10.1016/j.dnarep.2020.103025
- Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012 Nov 17;380(9855):1778-86. doi: 10.1016/S0140-6736(12)61611-0.
- Tsai HY, Tsai TY, Wu CH, Chung WS, Wang JC, Hsu JS, Hou MF, Chou MC. Integration of Clinical and CT-Based Radiomic Features for Pretreatment Prediction
- of Pathologic Complete Response to Neoadjuvant Systemic Therapy in Breast Cancer. Cancers (Basel). 2022 Dec 19;14(24):6261. doi: 10.3390/cancers14246261
- Zheng K, Luo Z, Zhou Y, Zhang L, Wang Y, Chen X, Yao S, Xiong H, Yuan X, Zou Y, Wang Y, Xiong H. A Framework to Predict the Molecular Classification and Prognosis of Breast Cancer Patients and Characterize the Landscape of Immune Cell Infiltration. Comput Math Methods Med. 2022 Jun 7;2022:4635806. doi: 10.1155/2022/4635806
- Li X, Zhang X, Liu J, Shen Y. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study. BMC Cancer. 2020 Nov 13;20(1):1102. doi: 10.1186/s12885-020-07593-8
Other articles of the issue
